Pfizer Q2 Adjusted EPS $0.67 Beats $0.57 Estimate, Sales $12.73B Miss $13.17B Estimate
Portfolio Pulse from Benzinga Newsdesk
Pfizer's Q2 earnings per share (EPS) of $0.67 beat the analyst consensus estimate of $0.57 by 17.54%, but represented a 67.16% decrease from the same period last year. The company's quarterly sales of $12.73 billion missed the analyst consensus estimate of $13.17 billion by 3.31%, and marked a 54.10% decrease from the same period last year.
August 01, 2023 | 10:50 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer's Q2 earnings beat estimates but were significantly lower than last year. Sales also missed estimates and were down from last year.
Pfizer's Q2 earnings beat analyst estimates, which could have a positive impact on the stock. However, the significant year-over-year decrease in both earnings and sales, as well as the missed sales estimate, could negatively impact the stock in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100